On February 9, 2017, Aurobindo Pharma Limited announced that it acquired four biosimilar products, including a biosimilar of Bevacizumab, from TL Biopharmaceutical AG. TL Biopharmaceutical is to supply developmental data for each acquired molecule and Aurobindo will be responsible for development, commercialization and marketing activities. Aurobindo expects to conduct clinical trials of the biosimilar of Bevacizumab in 2017.
Aurobindo currently has an R&D center for biologics development and expects to have a manufacturing facility ready by Q2 of its 2018 fiscal year.

Stay tuned to the Big Molecule Watch for further developments.